Hot Flashes Decoded: What's Actually Happening in Your Body

By Menopause Reviewed Editorial Team | Last reviewed: May 2026

Vasomotor symptoms — the clinical umbrella term for hot flashes and night sweats — affect approximately 75 percent of perimenopausal and postmenopausal women. For most, they are not a brief hormonal blip. A 2015 study published in JAMA Internal Medicine using data from the Study of Women's Health Across the Nation (SWAN), a longitudinal cohort tracking more than 1,400 women, found a median total duration of frequent vasomotor symptoms of 7.4 years. Among women who first reported symptoms while still menstruating, the median exceeded 11.8 years. Approximately 25 percent of women experience hot flashes for 10 years or longer, and up to 40 percent of women in their 60s continue to have them — well past the last menstrual period most people associate with menopause.

The experience is familiar: a sudden wave of heat beginning in the chest or face, spreading upward, often accompanied by visible flushing and drenching sweat. Heart rate rises. A chill follows. The whole episode lasts two to four minutes. Night versions disrupt sleep, which cascades into fatigue, mood instability, and impaired concentration. At peak frequency, the symptom is genuinely disabling — not merely inconvenient.

What is actually happening in the body has become substantially clearer over the past fifteen years. It starts in the brain.

The Mechanism: KNDy Neurons and the Narrowing Thermostat

The hypothalamus maintains core body temperature within a stable band — the thermoneutral zone — triggering sweating and skin vasodilation when temperature rises too high, and shivering when it drops too low. In women with hot flashes, this thermostat becomes pathologically sensitive. Research by physiologist Robert Freedman and colleagues, summarized in a 2014 review in the Journal of Steroid Biochemistry and Molecular Biology, measured the thermoneutral zone in symptomatic postmenopausal women at essentially 0.0°C, compared with 0.4°C in asymptomatic women. A temperature fluctuation that would normally pass unnoticed is enough to trigger a full heat-dissipation response.

For years, estrogen withdrawal was recognized as central to this narrowing, but the precise mechanism was unknown. A series of studies by Naomi Rance and colleagues at the University of Arizona — published in PNAS in 2012 and reviewed in Frontiers in Neuroendocrinology in 2013 — identified the key signaling pathway. In the arcuate (infundibular) nucleus of the hypothalamus, a specialized neuron population co-expresses three peptides: kisspeptin, neurokinin B (NKB), and dynorphin. These are collectively called KNDy neurons.

In premenopausal women, circulating estrogen suppresses KNDy neuron activity, keeping NKB output in check. When estrogen declines at menopause, that suppression is removed. KNDy neurons physically enlarge — hypertrophy — and markedly increase NKB secretion. These overactive neurons project from the arcuate nucleus to the median preoptic nucleus (MnPO) in the preoptic area of the hypothalamus, a core component of the brain's heat-defense pathway. Neurokinin B binds to the neurokinin 3 receptor (NK3R) in the MnPO and triggers the heat-dissipation cascade: cutaneous vasodilation, sweating, the sensation of intense internal heat.

A 2025 review in Temperature: Multidisciplinary Biomedical Journal confirmed that direct activation of KNDy neurons in mice produces a rise in tail-skin temperature followed by a transient drop in core temperature — exactly what a hot flash looks like physiologically. Genetic evidence adds further support: a genome-wide association study by Crandall and colleagues, drawing on three diverse cohorts totaling 17,695 postmenopausal women, found variants in TACR3, the gene encoding NK3R, to be significantly associated with vasomotor symptom risk.

In plain terms: estrogen declines → KNDy neurons disinhibit → excess neurokinin B floods the preoptic thermostat → a false heat alarm fires → the body launches a heat-dissipation response → hot flash. The thermoneutral zone is so compressed that ordinary daily temperature variation crosses the sweating threshold repeatedly.

What Triggers Individual Episodes

The underlying mechanism explains susceptibility, not timing. Several factors push core temperature above the sweating threshold or further compress the thermoneutral zone.

Ambient heat and external warming have the clearest evidence: hot environments, hot beverages, spicy food, and exercise all reliably provoke flashes in susceptible women. Stress and anxiety increase brain norepinephrine, which independently narrows the thermoneutral zone — explaining why paced breathing and clonidine (which reduces norepinephrine release) produce measurable reductions in flash frequency. Alcohol causes peripheral vasodilation and a secondary rise in core temperature; observational data consistently link it to increased flash frequency. Caffeine shows a weaker and more variable association in the SWAN data, possibly confounded by sleep disruption. Smoking is associated with moderately increased severity in observational studies. The evidence for most triggers is associative rather than causal, but the thermoregulatory mechanism provides a coherent biological rationale for each.

Treatments: What Works, and What Doesn't

Hormone Therapy — Gold Standard

Hormone therapy (HT) remains the most effective treatment for vasomotor symptoms by a wide margin. Meta-analyses consistently demonstrate 75 to 90 percent reductions in hot flash frequency with estrogen-based therapy. The mechanism is direct: exogenous estrogen restores KNDy neuron suppression, widening the thermoneutral zone. The 2022 Menopause Society Position Statement reaffirmed HT's primacy for vasomotor symptoms in healthy symptomatic women under 60 or within 10 years of menopause — a recalibration from the overcorrection that followed the 2002 Women's Health Initiative reporting. Evidence grade: strong.

Fezolinetant (Veozah) — First Non-Hormonal Drug Targeting the Mechanism

On May 12, 2023, the FDA approved fezolinetant (Veozah, Astellas Pharma), the first neurokinin 3 receptor antagonist approved for moderate to severe vasomotor symptoms. Rather than replacing estrogen, fezolinetant blocks NKB from binding to NK3R in the hypothalamus — interrupting the signaling cascade at its source.

The approval rested on the SKYLIGHT trial program. SKYLIGHT 1 (The Lancet, 2023) was a 12-week, randomized, double-blind, placebo-controlled trial with a 40-week active extension, enrolling women aged 40–65 with at least seven moderate-to-severe flashes per day. Both the 30 mg and 45 mg once-daily doses significantly reduced flash frequency and severity versus placebo by week 4, with improvements detectable within the first week and sustained through 52 weeks. SKYLIGHT 2 (Journal of Clinical Endocrinology and Metabolism, 2023) replicated these results in an identically designed trial. SKYLIGHT 4 was a 52-week safety-focused trial providing long-term tolerability data from approximately 2,200 women across the full program.

Common adverse effects include headache, fatigue, and abdominal pain. Approximately 2 percent of patients on 45 mg developed liver enzyme elevations above three times the upper limit of normal (versus 1 percent on placebo); the FDA requires periodic liver function monitoring and contraindicates the drug in women with hepatic impairment. Evidence grade: strong (Phase 3 RCTs, FDA-approved).

SSRIs, SNRIs, Gabapentin, and Oxybutynin

The only FDA-approved non-hormonal option before fezolinetant was paroxetine mesylate 7.5 mg (Brisdelle), a low-dose SSRI approved in 2013. Its mechanism in reducing hot flashes is not established; the FDA's own review notes the mechanism is unknown. Other SSRIs (escitalopram) and the SNRI venlafaxine reduce hot flash frequency by roughly 40 to 60 percent in clinical trials and are widely used off-label. Paroxetine should not be prescribed to women on tamoxifen, as it inhibits CYP2D6-mediated conversion to tamoxifen's active metabolite.

Gabapentin reduces flash frequency by 45 to 54 percent in RCTs at doses of 300 mg three times daily, though sedation limits tolerability. Oxybutynin, typically used for bladder overactivity, has shown hot flash reductions of approximately 70 percent in small trials and is increasingly used off-label with rapid onset. Evidence grade for this category: moderate.

Cognitive Behavioral Therapy (CBT)

Myra Hunter and colleagues at King's College London developed a CBT protocol specifically for hot flashes and night sweats, tested through the MENOS trial program. MENOS 2 (Menopause, 2012) was a multicenter RCT comparing group and self-help CBT to a waitlist control in perimenopausal and postmenopausal women. Both formats significantly reduced hot flash problem rating — the distress and functional interference associated with symptoms — at 6 and 26 weeks, with improvements in mood and quality of life. The MENOS@Work trial (Menopause, 2018) demonstrated that an unguided self-help CBT booklet produced significant reductions at 6 and 20 weeks in a workplace setting.

CBT does not substantially reduce physiologically measured flash frequency; its effect is on perceived severity and interference, which for many women is the more clinically relevant outcome. Evidence grade: moderate (multiple RCTs; targets distress rather than flash count).

Stellate Ganglion Block

A stellate ganglion block (SGB) — injection of local anesthetic into a sympathetic nerve cluster in the neck — is hypothesized to reduce hot flashes by dampening sympathetic tone and widening the thermoneutral zone. A 2023 RCT in Frontiers in Endocrinology (n=40) found significant improvements in hot flash score through 12 weeks. Evidence remains limited to small trials; the Menopause Society classifies SGB as a cautionary recommendation given the invasive nature and risks including hoarseness, Horner syndrome, and injection-site complications. Evidence grade: weak.

Cooling Strategies

Reducing the probability of crossing the sweating threshold has direct mechanistic support. Cooling pillows, moisture-wicking fabrics, portable fans, and layered clothing are low-risk and appropriate as first-line behavioral management alongside or instead of pharmacologic options.

What Does Not Work Despite the Hype

Phytoestrogens (soy isoflavones, red clover). A 2015 meta-analysis in Climacteric found a statistically significant but clinically small reduction — a mean difference of 0.89 fewer flashes per day across 10 trials. Multiple prior meta-analyses found no significant effect on menopausal symptom scores. The effect, where present, is modest and inconsistent.

Black cohosh. The 2012 Cochrane systematic review found no significant difference between black cohosh and placebo in hot flash frequency (mean difference: 0.07 flushes/day; 95% CI −0.43 to 0.56; P = 0.79; three trials, 393 women). Hormone therapy significantly outperformed black cohosh in all head-to-head comparisons in the review.

Acupuncture. A 2017 systematic review in Menopause found that acupuncture outperforms no treatment but consistently fails to outperform sham acupuncture across well-designed trials. Hot flashes are notably placebo-responsive, which likely accounts for the observed benefit versus no treatment.

Evening primrose oil. A 2024 systematic review in the Journal of Menopausal Medicine found no significant difference versus placebo in hot flash frequency (MD 0.44 flushes/day; 95% CI −1.32 to 2.20; P = 0.62), and no established mechanism by which it would affect thermoregulatory pathways.

When to Seek Further Evaluation

Most hot flashes in perimenopausal and early postmenopausal women require no workup beyond clinical history. Seek evaluation for secondary causes when:

• Flashes begin suddenly in a woman with no prior perimenopausal symptoms (consider medication effect, ovarian or adrenal cause)
• Severe flashes begin or persist in a woman in her mid-to-late 60s who has not previously experienced them (consider carcinoid syndrome, mastocytosis, lymphoma, pheochromocytoma)
• Flushing is accompanied by diarrhea, wheezing, or urticaria
• Onset correlates with a new medication (opioids, some antihypertensives, tamoxifen, aromatase inhibitors)

Bottom Line

Hot flashes are a specific thermoregulatory phenomenon caused by the disinhibition of KNDy neurons when estrogen declines — a mechanism now characterized at the molecular level. That same pathway explains why the two most effective treatments work: hormone therapy restores KNDy suppression through estrogen signaling, and fezolinetant blocks the neurokinin B receptor that triggers the heat-dissipation cascade. For women who cannot or prefer not to use either, SSRIs/SNRIs, gabapentin, and CBT offer meaningful but more modest benefit.

The SWAN data carry a practical message: hot flashes are likely to last longer than commonly assumed, with a median of 7.4 years and a significant minority exceeding a decade. Treatment decisions are easier with that context in hand.

References

1. Avis NE, Crawford SL, Greendale G, et al. Duration of Menopausal Vasomotor Symptoms Over the Menopause Transition. JAMA Internal Medicine. 2015. https://pmc.ncbi.nlm.nih.gov/articles/PMC4433164/

1. Freedman RR. Menopausal hot flashes: mechanisms, endocrinology, treatment. Journal of Steroid Biochemistry and Molecular Biology. 2014. https://pmc.ncbi.nlm.nih.gov/articles/PMC4612529/

1. Rance NE, Dacks PA, Mittelman-Smith MA, et al. Modulation of body temperature and LH secretion by hypothalamic KNDy neurons: A novel hypothesis on the mechanism of hot flushes. Frontiers in Neuroendocrinology. 2013. https://pmc.ncbi.nlm.nih.gov/articles/PMC3833827/

1. Mittelman-Smith MA, Williams H, Krajewski-Hall SJ, et al. Role for kisspeptin/neurokinin B/dynorphin (KNDy) neurons in cutaneous vasodilatation and the estrogen modulation of body temperature. PNAS. 2012. https://www.pnas.org/doi/10.1073/pnas.1211517109

1. Dacks PA, Krajewski SJ, Rance NE. Effects of menopause on temperature regulation. Temperature: Multidisciplinary Biomedical Journal. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12051537/

1. Waldstreicher J, McAuliffe A, Hutchison M, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms (SKYLIGHT 1). The Lancet. 2023. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00085-5/abstract00085-5/abstract)

1. Mirkin S, Nappi RE, Panay N, et al. Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms: SKYLIGHT 2. Journal of Clinical Endocrinology and Metabolism. 2023. https://academic.oup.com/jcem/article/108/8/1981/7025342

1. U.S. Food and Drug Administration. FDA Approves Veozah (fezolinetant) for Moderate to Severe Hot Flashes. May 12, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-novel-drug-treat-moderate-severe-hot-flashes-caused-menopause

1. The Menopause Society. The 2022 Hormone Therapy Position Statement. Menopause. 2022. https://pubmed.ncbi.nlm.nih.gov/35797481/

1. FDA Summary Review — Paroxetine mesylate (Brisdelle) NDA 204516. Approved June 28, 2013. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204516Orig1s000SumR.pdf

1. Ayers B, Mann E, Hunter MS. Effectiveness of group and self-help cognitive behavior therapy in reducing hot flush and night sweat frequency and problem rating (MENOS 2). Menopause. 2012. https://kclpure.kcl.ac.uk/portal/en/publications/effectiveness-of-group-and-self-help-cognitive-behavior-therapy-i/

1. Hardy C, Griffiths A, Norton S, Hunter MS. Self-help CBT for working women with hot flushes and night sweats (MENOS@Work). Menopause. 2018. https://pubmed.ncbi.nlm.nih.gov/29315132/

1. Zhao C, Yan C, Qi X, et al. Effects of stellate ganglion block on perimenopausal hot flashes. Frontiers in Endocrinology. 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10715304/

1. Lethaby A, Marjoribanks J, Kronenberg F, et al. Black cohosh (Cimicifuga spp.) for menopausal symptoms. Cochrane Database of Systematic Reviews. 2012. https://www.cochrane.org/evidence/CD007244_black-cohosh-cimicifuga-spp-menopausal-symptoms

1. Befus D, Coeytaux RR, Goldstein KM, et al. Acupuncture for menopausal hot flashes: clinical evidence synthesis. Menopause. 2017. https://pubmed.ncbi.nlm.nih.gov/28350757/